CU24475B1 - Receptor de antígeno quimérico con dominio de recepción de antígeno, anticuerpo conjugado y acoplador biespecífico de células t que se unen selectivamente a la región constante del trbc1 - Google Patents
Receptor de antígeno quimérico con dominio de recepción de antígeno, anticuerpo conjugado y acoplador biespecífico de células t que se unen selectivamente a la región constante del trbc1Info
- Publication number
- CU24475B1 CU24475B1 CU2016000129A CU20160129A CU24475B1 CU 24475 B1 CU24475 B1 CU 24475B1 CU 2016000129 A CU2016000129 A CU 2016000129A CU 20160129 A CU20160129 A CU 20160129A CU 24475 B1 CU24475 B1 CU 24475B1
- Authority
- CU
- Cuba
- Prior art keywords
- antigen
- trbc1
- bispecific
- constant region
- coupler
- Prior art date
Links
- 101000662909 Homo sapiens T cell receptor beta constant 1 Proteins 0.000 title abstract 4
- 102100037272 T cell receptor beta constant 1 Human genes 0.000 title abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 102000006306 Antigen Receptors Human genes 0.000 title 1
- 108010083359 Antigen Receptors Proteins 0.000 title 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
Abstract
<p>La presente invención se relaciona con un receptor antigénico quimérico (CAR) que comprende un dominio de unión a antígenos el cual se une selectivamente a la región constante del TCR beta 1 (TRBC1), un anticuerpo conjugado que se une selectivamente a TRBC1 y un acoplador biespecífico de células T que comprende un dominio que se une selectivamente a TRBC1. </p>
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201403905A GB201403905D0 (en) | 2014-03-05 | 2014-03-05 | Method |
GB201416908A GB201416908D0 (en) | 2014-09-25 | 2014-09-25 | Method |
PCT/GB2015/050643 WO2015132598A1 (en) | 2014-03-05 | 2015-03-05 | Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region |
Publications (1)
Publication Number | Publication Date |
---|---|
CU24475B1 true CU24475B1 (es) | 2020-03-04 |
Family
ID=52649058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2016000129A CU24475B1 (es) | 2014-03-05 | 2015-03-05 | Receptor de antígeno quimérico con dominio de recepción de antígeno, anticuerpo conjugado y acoplador biespecífico de células t que se unen selectivamente a la región constante del trbc1 |
Country Status (23)
Country | Link |
---|---|
US (2) | US20170066827A1 (es) |
EP (2) | EP3125934B1 (es) |
JP (5) | JP6767872B2 (es) |
KR (3) | KR102088082B1 (es) |
CN (3) | CN106068276B (es) |
AU (3) | AU2015225944B2 (es) |
BR (1) | BR112016020304B1 (es) |
CA (1) | CA2940564C (es) |
CL (4) | CL2016002195A1 (es) |
CU (1) | CU24475B1 (es) |
DK (1) | DK3125934T3 (es) |
ES (1) | ES2758173T3 (es) |
HU (1) | HUE047641T2 (es) |
IL (3) | IL278878B (es) |
MX (3) | MX2016010856A (es) |
MY (1) | MY173567A (es) |
PE (2) | PE20211887A1 (es) |
PH (2) | PH12016501646A1 (es) |
PL (1) | PL3125934T3 (es) |
PT (1) | PT3125934T (es) |
RU (3) | RU2018140694A (es) |
SG (3) | SG10201906460PA (es) |
WO (1) | WO2015132598A1 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11885807B2 (en) | 2014-03-05 | 2024-01-30 | Autolus Limited | Method for depleting malignant T-cells |
US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
WO2016051205A1 (en) * | 2014-10-03 | 2016-04-07 | Isis Innovation Limited | Analysis of t-cell monotypia |
CA2937157A1 (en) * | 2016-07-25 | 2018-01-25 | Ucl Business Plc | Protein-based t-cell receptor knockdown |
SG11201907299XA (en) | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
CA3053358A1 (en) * | 2017-04-04 | 2018-10-11 | F. Hoffmann-La Roche Ag | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap |
GB201709203D0 (en) * | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
EP3662055A1 (en) * | 2017-08-02 | 2020-06-10 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
IL311488A (en) * | 2017-08-23 | 2024-05-01 | Dragonfly Therapeutics Inc | Proteins that bind D2NKG, 16CD, and tumor-associated antigen |
WO2019129850A1 (en) * | 2017-12-29 | 2019-07-04 | Cellectis | Off-the-shelf engineered cells for therapy |
JP7372920B2 (ja) * | 2017-12-29 | 2023-11-01 | セレクティス | Car t細胞の作製を改良するための方法 |
GB201800298D0 (en) * | 2018-01-09 | 2018-02-21 | Autolus Ltd | Method |
US20200339687A1 (en) * | 2018-01-19 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting gamma delta t cells with chimeric antigen receptors |
WO2019157366A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
US20210283180A1 (en) * | 2018-07-06 | 2021-09-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Car t cell therapy to target t cell specific cancers |
WO2020018708A1 (en) * | 2018-07-18 | 2020-01-23 | The General Hospital Corporation | Compositions and methods for treatment of t cell malignancies |
GB201812650D0 (en) | 2018-08-03 | 2018-09-19 | Autolus Ltd | Molecular assessment of TRBC usage |
GB201817172D0 (en) | 2018-10-22 | 2018-12-05 | Autolus Ltd | Antibody |
US20220041718A1 (en) * | 2018-10-31 | 2022-02-10 | Autolus Limited | Binding domain |
EP3919515A4 (en) * | 2019-01-29 | 2022-11-23 | Shanghai Jiao Tong University | CHIMERA ANTIGEN RECEPTOR AND THEIR USE |
EP3927744A1 (en) * | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
CN110317266A (zh) * | 2019-07-17 | 2019-10-11 | 东北农业大学 | 三种scFv抗体、其编码基因及其在制备治疗或预防O型口蹄疫病制剂中的应用 |
EP4121518A4 (en) * | 2020-03-16 | 2024-06-19 | Marengo Therapeutics, Inc. | MANIPULATED CELL COMPOSITIONS AND METHODS OF USE THEREOF |
GB202004263D0 (en) | 2020-03-24 | 2020-05-06 | Autolus Ltd | Antibody conjugate |
GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
WO2021205175A1 (en) | 2020-04-09 | 2021-10-14 | Autolus Limited | Molecule |
GB202101491D0 (en) | 2021-02-03 | 2021-03-17 | Autolus Ltd | Molecule |
JP2023523011A (ja) * | 2020-04-24 | 2023-06-01 | マレンゴ・セラピューティクス,インコーポレーテッド | T細胞関連のがん細胞に結合する多機能性分子およびその使用 |
CN111537735A (zh) * | 2020-05-15 | 2020-08-14 | 江西赛基生物技术有限公司 | 抗体检测试剂盒以及在免疫分析方面的应用 |
CN111549044B (zh) * | 2020-07-13 | 2020-10-23 | 北京市肿瘤防治研究所 | 靶向trbc1 car-t细胞的制备方法与应用 |
WO2022038115A1 (en) * | 2020-08-18 | 2022-02-24 | Medigene Immunotherapies Gmbh | ENRICHMENT OF T CELLS USING AN ANTI-Cß ANTIBODY |
AU2021333779A1 (en) * | 2020-08-26 | 2023-04-13 | Marengo Therapeutics, Inc. | Methods of detecting TRBC1 or TRBC2 |
AU2022222679A1 (en) | 2021-02-17 | 2023-09-07 | The Johns Hopkins University | Methods and materials for treating clonal t cell expansions |
WO2022177870A1 (en) * | 2021-02-17 | 2022-08-25 | The Board Of Regents Of The University Of Texas System | Multimeric sars-cov-2 binding molecules and uses thereof |
GB202112923D0 (en) * | 2021-09-10 | 2021-10-27 | Ucl Business Ltd | Binding domain |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06502529A (ja) * | 1990-08-09 | 1994-03-24 | ナショナル ジューイッシュ センター フォア イミュノロジィ アンド レスパラトリィ メディスン | 組換えdnaベクターを使用するヒトt細胞受容体要素に対するモノクローナル抗体の製造方法 |
US6790604B1 (en) * | 1998-05-12 | 2004-09-14 | Stefan A. Cohen | Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells |
WO2003093318A1 (en) * | 2002-04-29 | 2003-11-13 | Genpat77 Pharmacogenetics Ag | Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis |
RU2355703C2 (ru) * | 2002-10-09 | 2009-05-20 | Медиджен Лимитед | Одноцепочечные рекомбинантные т-клеточные рецепторы |
GB0304068D0 (en) * | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
US7741045B2 (en) * | 2006-11-16 | 2010-06-22 | General Electric Company | Sequential analysis of biological samples |
WO2009151628A2 (en) * | 2008-06-12 | 2009-12-17 | Gov't Of The Usa, As Represented By The Secretary, Department Of Health Human Services | Monitoring tcr-b to determine hiv therapy and disease progression |
CA2735193A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics, Inc. | T-cell receptor antibodies and methods of use thereof |
ME02505B (me) * | 2009-12-29 | 2017-02-20 | Aptevo Res & Development Llc | Heterodimerni vezujući proteini i njihove upotrebe |
JP6000507B2 (ja) * | 2010-09-30 | 2016-09-28 | パナソニックヘルスケアホールディングス株式会社 | 診療情報登録装置 |
BR122021026169B1 (pt) * | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
WO2013176916A1 (en) * | 2012-05-25 | 2013-11-28 | Roman Galetto | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
US10443100B2 (en) * | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
BR112017005245A2 (pt) * | 2014-09-19 | 2017-12-12 | Regeneron Pharma | animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos. |
BR112017020750A2 (pt) * | 2015-03-27 | 2018-06-26 | Harvard College | células t modificadas e métodos de produção e utilização das mesmas |
-
2015
- 2015-03-05 CN CN201580011306.XA patent/CN106068276B/zh active Active
- 2015-03-05 EP EP15709319.6A patent/EP3125934B1/en active Active
- 2015-03-05 KR KR1020167027423A patent/KR102088082B1/ko active IP Right Grant
- 2015-03-05 PE PE2021000759A patent/PE20211887A1/es unknown
- 2015-03-05 BR BR112016020304-6A patent/BR112016020304B1/pt active IP Right Grant
- 2015-03-05 RU RU2018140694A patent/RU2018140694A/ru unknown
- 2015-03-05 CN CN202010859460.5A patent/CN112094353A/zh active Pending
- 2015-03-05 WO PCT/GB2015/050643 patent/WO2015132598A1/en active Application Filing
- 2015-03-05 IL IL278878A patent/IL278878B/en unknown
- 2015-03-05 MY MYPI2016703188A patent/MY173567A/en unknown
- 2015-03-05 RU RU2021101502A patent/RU2021101502A/ru unknown
- 2015-03-05 US US15/123,287 patent/US20170066827A1/en not_active Abandoned
- 2015-03-05 PL PL15709319T patent/PL3125934T3/pl unknown
- 2015-03-05 EP EP17172755.5A patent/EP3241561A1/en active Pending
- 2015-03-05 CN CN202010858243.4A patent/CN112094347A/zh active Pending
- 2015-03-05 PE PE2016001548A patent/PE20170125A1/es unknown
- 2015-03-05 KR KR1020207006445A patent/KR102235202B1/ko active IP Right Grant
- 2015-03-05 DK DK15709319.6T patent/DK3125934T3/da active
- 2015-03-05 SG SG10201906460PA patent/SG10201906460PA/en unknown
- 2015-03-05 JP JP2016554603A patent/JP6767872B2/ja active Active
- 2015-03-05 SG SG10201906461SA patent/SG10201906461SA/en unknown
- 2015-03-05 MX MX2016010856A patent/MX2016010856A/es active IP Right Grant
- 2015-03-05 CA CA2940564A patent/CA2940564C/en active Active
- 2015-03-05 HU HUE15709319A patent/HUE047641T2/hu unknown
- 2015-03-05 CU CU2016000129A patent/CU24475B1/es unknown
- 2015-03-05 RU RU2016138421A patent/RU2744046C2/ru active
- 2015-03-05 PT PT157093196T patent/PT3125934T/pt unknown
- 2015-03-05 SG SG11201606583VA patent/SG11201606583VA/en unknown
- 2015-03-05 KR KR1020207006444A patent/KR102235201B1/ko active IP Right Grant
- 2015-03-05 ES ES15709319T patent/ES2758173T3/es active Active
- 2015-03-05 AU AU2015225944A patent/AU2015225944B2/en active Active
-
2016
- 2016-08-04 IL IL247110A patent/IL247110A0/en active IP Right Grant
- 2016-08-17 PH PH12016501646A patent/PH12016501646A1/en unknown
- 2016-08-19 MX MX2019013846A patent/MX2019013846A/es unknown
- 2016-08-19 MX MX2019013845A patent/MX2019013845A/es unknown
- 2016-09-01 CL CL2016002195A patent/CL2016002195A1/es unknown
-
2017
- 2017-05-26 US US15/606,480 patent/US20170334998A1/en not_active Abandoned
- 2017-05-31 JP JP2017107689A patent/JP6767931B2/ja active Active
-
2018
- 2018-10-30 CL CL2018003096A patent/CL2018003096A1/es unknown
-
2019
- 2019-06-07 CL CL2019001567A patent/CL2019001567A1/es unknown
- 2019-06-07 CL CL2019001568A patent/CL2019001568A1/es unknown
- 2019-07-09 AU AU2019204925A patent/AU2019204925B2/en active Active
- 2019-07-09 AU AU2019204921A patent/AU2019204921C1/en active Active
-
2020
- 2020-03-25 JP JP2020054667A patent/JP7149304B2/ja active Active
- 2020-04-01 PH PH12020550203A patent/PH12020550203A1/en unknown
- 2020-11-22 IL IL278879A patent/IL278879A/en unknown
-
2021
- 2021-09-15 JP JP2021150189A patent/JP2021184773A/ja not_active Withdrawn
-
2024
- 2024-04-03 JP JP2024060080A patent/JP2024074907A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU24475B1 (es) | Receptor de antígeno quimérico con dominio de recepción de antígeno, anticuerpo conjugado y acoplador biespecífico de células t que se unen selectivamente a la región constante del trbc1 | |
CY1124993T1 (el) | Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20 | |
CY1125032T1 (el) | Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου | |
CL2017003195A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso. | |
PH12018500861A1 (en) | Antibody/t-cell receptor chimeric constructs and uses thereof | |
NZ731778A (en) | Cell which co-expresses a cd19 chimeric antigen receptor | |
HK1257748A1 (zh) | 雙特異性t細胞嚙合抗體構築體 | |
ECSP21060675A (es) | Receptores de antígenos quiméricos de gprc5d y células que los expresan | |
HK1257749A1 (zh) | Psma及cd3雙特異性t細胞嚙合抗體構築體 | |
CL2017001361A1 (es) | Anticuerpos heterodiméricos que se unen a cd3 y cd38 | |
CO2017006740A2 (es) | Anticuerpos anti–cd79b | |
CL2017000545A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
MX2017003640A (es) | Receptores antigenicos quimericos. | |
UY36968A (es) | Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll | |
CR20220186A (es) | ANTICUERPOS ANTI-TIGIT Y MÉTODOS DE USO (divisional 2018-0225) | |
CU24446B1 (es) | Un anticuerpo monoclonal humanizado que se une a tau | |
AR114284A1 (es) | Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl | |
CO2019002369A2 (es) | Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo | |
IL271832A (en) | Bispecific antibodies against PD1 and against TIM3 | |
MX2023006786A (es) | Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control. | |
EP3478320A4 (en) | MONOCLONAL ANTIBODIES AGAINST SIGNALING OF THE KILLERIMMUNOGLOBULIN LIKE RECIPE (KIR) FAMILY | |
MX2019002349A (es) | Anticuerpos inmunomoduladores biespecíficos que se fijan a receptores coestimuladores y de puntos de control. |